Home/Filings/4/0001615219-25-000177
4//SEC Filing

Rosenblum Mark J 4

Accession 0001615219-25-000177

CIK 0001615219other

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 4:42 PM ET

Size

5.0 KB

Accession

0001615219-25-000177

Insider Transaction Report

Form 4
Period: 2025-11-20
Rosenblum Mark J
Exec VP Finance, CFO
Transactions
  • Purchase

    Common Stock

    2025-11-20$0.80/sh+20,000$16,00020,177 total
Footnotes (2)
  • [F1]Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025.
  • [F2]Includes 20 shares of unvested restricted stock granted on January 3, 2023.

Issuer

Salarius Pharmaceuticals, Inc.

CIK 0001615219

Entity typeother

Related Parties

1
  • filerCIK 0001329154

Filing Metadata

Form type
4
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 4:42 PM ET
Size
5.0 KB